Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

Affibody completes 12-week interim analysis of phase II psoriasis study of ABY-035

July 17, 2019

Galderma describes new mTOR inhibitors

July 15, 2019

Pfizer initiates phase II study of PF-06826647 for the treatment of plaque psoriasis

July 12, 2019

First patient dosed in phase II study of KD-025 in cutaneous systemic sclerosis

July 11, 2019

Cara initiates phase II trial of oral difelikefalin to treat pruritus in atopic dermatitis

July 10, 2019

Zhengzhou University describes Helicobacter pylori-neutrophil activating proteins

July 9, 2019

Promising topline results presented from phase III program of Epsolay in papulopustular rosacea

July 9, 2019

Almirall identifies acetyl-CoA carboxylase inhibitors

July 8, 2019

Leo Pharma patents PDE4 inhibitors

July 4, 2019

Leo Pharma describes PDE4 and TNF-alpha release inhibitors

July 3, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...